… drug, Enhertu. Following the announcement, AstraZeneca’s shares became one of … confidence was further boosted by AstraZeneca’s fourth-quarter results, which … rates. Despite the positive outlook, AstraZeneca cautioned that challenges remain, including …

… The Anglo-Swedish pharmaceutical giant AstraZeneca faces mounting pressure from shareholders … unease among Nordic investors, with AstraZeneca shareholder Lucy Coutts from investment … executives, concerning the import of AstraZeneca cancer drugs from Hong Kong …

… In July last year, AstraZeneca’s chief executive, Pascal Soriot … by government incentives. In AstraZeneca’s case, Dix put … revised to £78m. But AstraZeneca wanted the government to honour … were all very disappointed.” AstraZeneca’s breast cancer drug Enhertu …

AstraZeneca’s diabetes drug Bydureon (exenatide) …

… a class action lawsuit against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ … investors who purchased or acquired AstraZeneca common stock between February 23 … . When investors learned the truth, AstraZeneca’s common stock declined precipitously …

… notifies investors in AstraZeneca PLC ("AstraZeneca" or the … on behalf of AstraZeneca investors who were … eventually resulted in the AstraZeneca China President being detained … revealed, could materially harm AstraZeneca’s business activities in …

… Liverpool, where the pharmaceutical company AstraZeneca would be manufacturing vaccines. Last … the [...] proposed investment [by AstraZeneca], resulting in a smaller level … questions. Firstly, some context. AstraZeneca, a pharma and biotechnology business …

… and urges investors in AstraZeneca American Depositary Shares who … reportedly centers on allegations that AstraZeneca employees improperly imported cancer … frequently asked questions about the AstraZeneca investigation, read more » Whistleblowers: …

… of AIM’s Ampligen and AstraZeneca’s FluMist, a nasal spray … avian influenza when combined with AstraZeneca’s FluMist vaccine. Based on …